Neurowyzr is a company that focuses on early detection, diagnosis, therapy, monitoring, and prevention of brain decline.

Neurowyzr

We protect quality of life and optimise personal potential by enabling early detection, diagnosis, therapy, monitoring and prevention of brain decline. Built on clinical evidence and powered by advanced analytics and AI, we provide a complete suite of gamified digital assessments and omni-platform care to bring brain health and mental wellbeing to everyone.

Peak XV Partners

Jungle Ventures

Abhishek Gaur

Khoo Boon Hui

Rob F Jablonski

🦁 Happy National Day, Singapore! Together, let's continue building a prosperous, healthier and stronger nation. Majulah Singapura!

We strive to be a catalyst for collaborations between key movers that make brain healthcare as accessible as possible. 

Email us at hello@neurowyzr.com for collaborations 🤝

#wbd #worldbrainday2024 #healthcareprofessionals #researchers #policymakers

Everyone should have access to early brain healthcare to prevent severe neurological conditions. At Neurowyzr, we support community partners screen for early brain decline to help as many people, regardless of their background. #wbd #worldbrainday2024 #prevention #communityscreening

Be proactive and schedule your brain health screening annually! Your future self (and brain) will thank you.

Find a brain health screening provider here:
https://lnkd.in/gDiRxK5Y

#wbd #worldbrainday2024 #neurologicaldisorders

Happy World Brain Day! In line with this year's theme, 'Protecting Our Future', stay tuned for content about community brain health and disease prevention throughout the week. Everyone needs to play their part to protect our future. 

World Federation Of Neurology

#wbd #worldbrainday #prevention

Neurowyzr has been awarded the New Technology Solution Disruptor of the Year in Asia Pacific at the Global Health MedTech Awards 2024! This prestigious recognition is a testament to our unwavering commitment to innovation in brain health technology. We strive to develop more deep neuroscience digital solutions that help to screen, monitor, assess, and improve brain health, like our award-winning Digital Brain Function Screen (DBFS). Thank you to everyone who has been supportive of us thus far!

#GlobalHealthAwards #MedTech #Innovation #BrainHealth #HealthcareTechnology #Neurowyzr #AwardWinning #HealthcareInnovation #DBFS #brainfunction

Metric
Company Name	Neurowyzr
Symbol
MSH ID	COM:NEUROWYZR
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Digital Health and Neuroscience
Country	SG
Stage
Employee Count	28
Website	neurowyzr.com
LinkedIn	neurowyzr
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:NEUROWYZR

Neurowyzr

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue